• 1
    Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005; 205: 24854.
  • 2
    Suen D, Chow LWC. Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer. Biomed Pharmacother 2006; 60: 2937.
  • 3
    Dorr FA. Prognostic factors observed in current clinical-trials. Cancer 1993; 71: 21638.
  • 4
    Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2008; 100: 3240.
  • 5
    Fjosne HE, Jacobsen AB, Lundgren S; Norwegian Breast Cancer Group (NBCG). Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients—longterm follow-up. Eur J Surg Oncol 2008; 34: 612.
  • 6
    Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 2007; 146: 51626.
  • 7
    Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, Shen TZ, Hade EM, Young GS, Jarjoura D. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008; 26: 2537.
  • 8
    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 122.
  • 9
    Bergh J, Jonsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40: 25381.
  • 10
    Pusztai L, HortobagyiGN. High-dose chemotherapy: how resistant is breast cancer? Drug Resist Updat 1998; 1: 6272.
  • 11
    O'Shaughnessy J. Developments in the systemic therapy of early-stage breast cancer. Eur J Cancer Suppl 2007; 5: 310.
  • 12
    Chiew KS, Shepherd H, Vardy J, Tattersall MHN, Butow PN, Leighl NB. Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. Health Expect 2008; 11: 3545.
  • 13
    National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 2001;( 30): 515.
  • 14
    Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, et al. NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) 2000; 14: 3349.
  • 15
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 381727.
  • 16
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005; 16: 156983.
  • 17
    Dinh P, Sotiriou C, Piccart MJ. The evolution of treatment strategies: aiming at the target. Breast 2007; 16: S106.
  • 18
    Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005; 92: 6975.
  • 19
    Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 2008; 13: 37.
  • 20
    Mauriac L, Debled M, MacGrogan G. When will more useful predictive factors be ready for use? Breast 2005; 14: 61723.
  • 21
    van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004; 57: 67581.
  • 22
    Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65: 405966.
  • 23
    Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 172339.
  • 24
    Wu YL, Luo HY, Kanaan N, Wu JP. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000; 76: 596604.
  • 25
    Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002; 40: 211.
  • 26
    Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000; 257: 2317.
  • 27
    Finek J, Holubec L,Jr, Topolcan O, Elgrova L, Skalova A, Pecen L. The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res 2007; 27: 18936.
  • 28
    Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002; 98: 11827.
  • 29
    de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 150413.
  • 30
    Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 34050.
  • 31
    Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AHS, Robertson JF, Blamey RW, Macmillan D, Ellis IO. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 314956.
  • 32
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 72529.
  • 33
    Weigelt B, Hu ZY, He XP, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65: 91558.
  • 34
    Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006; 11: 54152.
  • 35
    Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol 2006; 18: 248.
  • 36
    Groenvold M, Fayers PM, Petersen MA, Sprangers MAG, Aaronson NK, Mouridsen HT. Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. Breast Cancer Res Treat 2007; 103: 18595.
  • 37
    Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008; 107: 30930.
  • 38
    Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002; 98: 11827.
  • 39
    Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Janicke F, Nathrath W, Schmitt M, Graeff H, Hofler H. Prognostic impact of proliferation associated factors MIBI (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 1997; 75: 152533.
  • 40
    Kaaijk P, Kaspers GJL, van Wering ER, Broekema GJ, Loonen AH, Hahlen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJP. Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer 2003; 88: 77581.
  • 41
    Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 556975.
  • 42
    Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V. Correlation between MIB-1 and other proliferation markers—clinical implications of the MIB-1 cutoff value. Cancer 2002; 94: 21519.
  • 43
    Bai M, Agnantis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A, Kanavaros P. In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res 2001; 3: 27683.
  • 44
    Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
  • 45
    Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 73650.